{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,31]],"date-time":"2026-01-31T16:44:37Z","timestamp":1769877877523,"version":"3.49.0"},"reference-count":32,"publisher":"Springer Science and Business Media LLC","issue":"1","funder":[{"DOI":"10.13039\/501100000015","name":"Canadian Cancer Society Research Institute","doi-asserted-by":"publisher","award":["703037"],"award-info":[{"award-number":["703037"]}],"id":[{"id":"10.13039\/501100000015","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000015","name":"Canadian Cancer Society Research Institute","doi-asserted-by":"publisher","award":["702786"],"award-info":[{"award-number":["702786"]}],"id":[{"id":"10.13039\/501100000015","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000024","name":"Canadian Institutes of Health Research","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000024","id-type":"DOI","asserted-by":"publisher"}]},{"name":"VGH Hospital Foundation"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Cancer"],"published-print":{"date-parts":[[2018,12]]},"DOI":"10.1186\/s12885-018-4153-8","type":"journal-article","created":{"date-parts":[[2018,3,5]],"date-time":"2018-03-05T06:37:08Z","timestamp":1520231828000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":20,"title":["A population-based analysis of germline BRCA1 and BRCA2 testing among ovarian cancer patients in an era of histotype-specific approaches to ovarian cancer prevention"],"prefix":"10.1186","volume":"18","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9594-0545","authenticated-orcid":false,"given":"Gillian E.","family":"Hanley","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jessica N.","family":"McAlpine","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dianne","family":"Miller","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David","family":"Huntsman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kasmintan A.","family":"Schrader","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C.","family":"Blake Gilks","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gillian","family":"Mitchell","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2018,3,5]]},"reference":[{"key":"4153_CR1","unstructured":"Canadian Cancer Society. Canadian cancer statistics 2014. Toronto, Canada; 2014. http:\/\/www.cancer.ca\/en\/cancer-information\/cancer-101\/canadian-cancer-statistics-publication\/?region=sk . Accessed 27 Feb 2018."},{"issue":"11","key":"4153_CR2","doi-asserted-by":"publisher","first-page":"812","DOI":"10.1093\/jnci\/djt095","volume":"105","author":"N Mavaddat","year":"2013","unstructured":"Mavaddat N, Peock S, Frost D, Ellis S, Platte R, Fineberg E, et al. Cancer risks for BRCA1 and BRCA2 mutation carriers: results from prospective analysis of EMBRACE. J Natl Cancer Inst. 2013;105(11):812\u201322.","journal-title":"J Natl Cancer Inst"},{"issue":"1 Pt 2","key":"4153_CR3","doi-asserted-by":"publisher","first-page":"S8","DOI":"10.1006\/gyno.2002.6674","volume":"88","author":"J Boyd","year":"2003","unstructured":"Boyd J. Specific keynote: hereditary ovarian cancer: what we know. Gynecologic oncology. 2003;88(1 Pt 2):S8\u201310. discussion S1\u20133","journal-title":"Gynecologic oncology"},{"issue":"5645","key":"4153_CR4","doi-asserted-by":"publisher","first-page":"643","DOI":"10.1126\/science.1088759","volume":"302","author":"MC King","year":"2003","unstructured":"King MC, Marks JH, Mandell JB. New York breast cancer study G. Breast and ovarian cancer risks due to inherited mutations in BRCA1 and BRCA2. Science. 2003;302(5645):643\u20136.","journal-title":"Science"},{"issue":"8","key":"4153_CR5","doi-asserted-by":"publisher","first-page":"861","DOI":"10.1016\/j.humpath.2005.06.006","volume":"36","author":"J Prat","year":"2005","unstructured":"Prat J, Ribe A, Gallardo A. Hereditary ovarian cancer. Hum Pathol. 2005;36(8):861\u201370.","journal-title":"Hum Pathol"},{"issue":"23","key":"4153_CR6","doi-asserted-by":"publisher","first-page":"1694","DOI":"10.1093\/jnci\/djj465","volume":"98","author":"HA Risch","year":"2006","unstructured":"Risch HA, McLaughlin JR, Cole DE, Rosen B, Bradley L, Fan I, et al. Population BRCA1 and BRCA2 mutation frequencies and cancer penetrances: a kin-cohort study in Ontario, Canada. J Natl Cancer Inst. 2006;98(23):1694\u2013706.","journal-title":"J Natl Cancer Inst"},{"issue":"12","key":"4153_CR7","doi-asserted-by":"publisher","first-page":"2807","DOI":"10.1002\/cncr.21536","volume":"104","author":"T Pal","year":"2005","unstructured":"Pal T, Permuth-Wey J, Betts JA, Krischer JP, Fiorica J, Arango H, et al. BRCA1 and BRCA2 mutations account for a large proportion of ovarian carcinoma cases. Cancer. 2005;104(12):2807\u201316.","journal-title":"Cancer"},{"issue":"3","key":"4153_CR8","doi-asserted-by":"publisher","first-page":"700","DOI":"10.1086\/318787","volume":"68","author":"HA Risch","year":"2001","unstructured":"Risch HA, McLaughlin JR, Cole DE, Rosen B, Bradley L, Kwan E, et al. Prevalence and penetrance of germline BRCA1 and BRCA2 mutations in a population series of 649 women with ovarian cancer. Am J Hum Genet. 2001;68(3):700\u201310.","journal-title":"Am J Hum Genet"},{"issue":"21","key":"4153_CR9","doi-asserted-by":"publisher","first-page":"2654","DOI":"10.1200\/JCO.2011.39.8545","volume":"30","author":"K Alsop","year":"2012","unstructured":"Alsop K, Fereday S, Meldrum C, de Fazio A, Emmanuel C, George J, et al. BRCA mutation frequency and patterns of treatment response in BRCA mutation-positive women with ovarian cancer: a report from the Australian ovarian cancer study group. [erratum appears in J Clin Oncol. 2012 Nov 20;30(33):4180]. J Clin Oncol. 2012;30(21):2654\u201363.","journal-title":"J Clin Oncol"},{"issue":"2 Pt 1","key":"4153_CR10","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1097\/AOG.0b013e31825f3576","volume":"120","author":"KA Schrader","year":"2012","unstructured":"Schrader KA, Hurlburt J, Kalloger SE, Hansford S, Young S, Huntsman DG, et al. Germline BRCA1 and BRCA2 mutations in ovarian cancer: utility of a histology-based referral strategy. Obstet Gynecol. 2012;120(2 Pt 1):235\u201340.","journal-title":"Obstet Gynecol"},{"issue":"1","key":"4153_CR11","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1200\/JCO.2011.39.7638","volume":"31","author":"AN Rosenthal","year":"2013","unstructured":"Rosenthal AN, Fraser L, Manchanda R, Badman P, Philpott S, Mozersky J, et al. Results of annual screening in phase I of the United Kingdom familial ovarian cancer screening study highlight the need for strict adherence to screening schedule. J Clin Oncol. 2013;31(1):49\u201357.","journal-title":"J Clin Oncol"},{"issue":"33","key":"4153_CR12","doi-asserted-by":"publisher","first-page":"4188","DOI":"10.1200\/JCO.2013.48.9021","volume":"31","author":"PG Moorman","year":"2013","unstructured":"Moorman PG, Havrilesky LJ, Gierisch JM, Coeytaux RR, Lowery WJ, Peragallo Urrutia R, et al. Oral contraceptives and risk of ovarian cancer and breast cancer among high-risk women: a systematic review and meta-analysis. J Clin Oncol. 2013;31(33):4188\u201398.","journal-title":"J Clin Oncol"},{"issue":"2","key":"4153_CR13","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1001\/jama.296.2.185","volume":"296","author":"A Finch","year":"2006","unstructured":"Finch A, Beiner M, Lubinski J, Lynch HT, Moller P, Rosen B, et al. Salpingo-oophorectomy and the risk of ovarian, fallopian tube, and peritoneal cancers in women with a BRCA1 or BRCA2 mutation. JAMA. 2006;296(2):185\u201392.","journal-title":"JAMA"},{"issue":"8","key":"4153_CR14","doi-asserted-by":"publisher","first-page":"1331","DOI":"10.1200\/JCO.2007.13.9626","volume":"26","author":"ND Kauff","year":"2008","unstructured":"Kauff ND, Domchek SM, Friebel TM, Robson ME, Lee J, Garber JE, et al. Risk-reducing salpingo-oophorectomy for the prevention of BRCA1- and BRCA2-associated breast and gynecologic cancer: a multicenter, prospective study. J Clin Oncol. 2008;26(8):1331\u20137.","journal-title":"J Clin Oncol"},{"issue":"9","key":"4153_CR15","doi-asserted-by":"publisher","first-page":"967","DOI":"10.1001\/jama.2010.1237","volume":"304","author":"SM Domchek","year":"2010","unstructured":"Domchek SM, Friebel TM, Singer CF, Evans DG, Lynch HT, Isaacs C, et al. Association of risk-reducing surgery in BRCA1 or BRCA2 mutation carriers with cancer risk and mortality. JAMA. 2010;304(9):967\u201375.","journal-title":"JAMA"},{"key":"4153_CR16","doi-asserted-by":"publisher","first-page":"740968","DOI":"10.1155\/2010\/740968","volume":"2010","author":"CB Gilks","year":"2010","unstructured":"Gilks CB. Molecular abnormalities in ovarian cancer subtypes other than high-grade serous carcinoma. J Oncol. 2010;2010:740968.","journal-title":"J Oncol"},{"issue":"3","key":"4153_CR17","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1097\/PGP.0b013e3181c042b6","volume":"29","author":"M Kobel","year":"2010","unstructured":"Kobel M, Kalloger SE, Huntsman DG, Santos JL, Swenerton KD, Seidman JD, et al. Differences in tumor type in low-stage versus high-stage ovarian carcinomas. Int J Gynecol Path. 2010;29(3):203\u201311.","journal-title":"Int J Gynecol Path"},{"key":"4153_CR18","doi-asserted-by":"publisher","unstructured":"Singh N, McCluggage WG, Gilks CB. High grade serous carcinoma (HGSC) of tubo-ovarian origin: recent developments. Histopathol. 2017; https:\/\/doi.org\/10.1111\/his.13248 .","DOI":"10.1111\/his.13248"},{"issue":"2","key":"4153_CR19","doi-asserted-by":"publisher","first-page":"353","DOI":"10.1016\/j.ygyno.2011.01.020","volume":"121","author":"S Zhang","year":"2011","unstructured":"Zhang S, Royer R, Li S, McLaughlin JR, Rosen B, Risch HA, et al. Frequencies of BRCA1 and BRCA2 mutations among 1,342 unselected patients with invasive ovarian cancer. Gynecol Oncol. 2011;121(2):353\u20137.","journal-title":"Gynecol Oncol"},{"issue":"4","key":"4153_CR20","doi-asserted-by":"publisher","first-page":"407","DOI":"10.1097\/00004347-200210000-00011","volume":"21","author":"PA Shaw","year":"2002","unstructured":"Shaw PA, McLaughlin JR, Zweemer RP, Narod SA, Risch H, Verheijen RH, et al. Histopathologic features of genetically determined ovarian cancer. Int J Gynecol Path. 2002;21(4):407\u201311.","journal-title":"Int J Gynecol Path."},{"issue":"6","key":"4153_CR21","doi-asserted-by":"publisher","first-page":"856","DOI":"10.1038\/ng.3849","volume":"49","author":"YK Wang","year":"2017","unstructured":"Wang YK, Bashashati A, Anglesio MS, Cochrane DR, Grewal DS, Ha G, et al. Genomic consequences of aberrant DNA repair mechanisms stratify ovarian cancer histotypes. Nat Genet. 2017;49(6):856\u201365.","journal-title":"Nat Genet"},{"key":"4153_CR22","unstructured":"BC Cancer Agency Registry Data (2015). V2. Population Data BC .Data Extract. BC Cancer Agency. www.popdata.bc.ca ."},{"key":"4153_CR23","unstructured":"BC Vital Statistics Agency (2015): Vital Statistics Deaths. V2. BC Vital Statistics Agency. 2015 www.popdata.bc.ca ."},{"issue":"5","key":"4153_CR24","doi-asserted-by":"publisher","first-page":"471 e1","DOI":"10.1016\/j.ajog.2014.01.003","volume":"210","author":"JN McAlpine","year":"2014","unstructured":"McAlpine JN, Hanley GE, Woo MM, Tone AA, Rozenberg N, Swenerton KD, et al. Opportunistic salpingectomy: uptake, risks, and complications of a regional initiative for ovarian cancer prevention. Am J Obstet Gynecol. 2014;210(5):471 e1\u201311.","journal-title":"Am J Obstet Gynecol"},{"issue":"22","key":"4153_CR25","doi-asserted-by":"publisher","first-page":"3570","DOI":"10.1200\/JCO.2009.27.2997","volume":"28","author":"BT Hennessy","year":"2010","unstructured":"Hennessy BT, Timms KM, Carey MS, Gutin A, Meyer LA, Flake DD 2nd, et al. Somatic mutations in BRCA1 and BRCA2 could expand the number of patients that benefit from poly (ADP ribose) polymerase inhibitors in ovarian cancer. J Clin Onc. 2010;28(22):3570\u20136.","journal-title":"J Clin Onc"},{"key":"4153_CR26","doi-asserted-by":"crossref","unstructured":"Kobel M, Bak J, Bertelsen BI, Carpen O, Grove A, Hansen ES, et al. Ovarian carcinoma histotype determination is highly reproducible, and is improved through the use of immunohistochemistry. Histopathol. 64(7):1004\u201313.","DOI":"10.1111\/his.12349"},{"issue":"2","key":"4153_CR27","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1016\/j.ygyno.2015.12.020","volume":"140","author":"SM Domchek","year":"2016","unstructured":"Domchek SM, Aghajanian C, Shapira-Frommer R, Schmutzler RK, Audeh MW, Friedlander M, et al. Efficacy and safety of olaparib monotherapy in germline BRCA1\/2 mutation carriers with advanced ovarian cancer and three or more lines of prior therapy. Gynecol Oncol. 2016;140(2):199\u2013203.","journal-title":"Gynecol Oncol"},{"issue":"8","key":"4153_CR28","doi-asserted-by":"publisher","first-page":"852","DOI":"10.1016\/S1470-2045(14)70228-1","volume":"15","author":"J Ledermann","year":"2014","unstructured":"Ledermann J, Harter P, Gourley C, Friedlander M, Vergote I, Rustin G, et al. Olaparib maintenance therapy in patients with platinum-sensitive relapsed serous ovarian cancer: a preplanned retrospective analysis of outcomes by BRCA status in a randomised phase 2 trial. Lancet Oncol. 2014;15(8):852\u201361.","journal-title":"Lancet Oncol"},{"issue":"7","key":"4153_CR29","doi-asserted-by":"publisher","first-page":"1574","DOI":"10.1158\/1078-0432.CCR-14-2565","volume":"21","author":"S Kummar","year":"2015","unstructured":"Kummar S, Oza AM, Fleming GF, Sullivan DM, Gandara DR, Naughton MJ, et al. Randomized trial of oral cyclophosphamide and Veliparib in high-grade serous ovarian, primary peritoneal, or fallopian tube cancers, or BRCA-mutant ovarian cancer. Clin Cancer Res. 2015;21(7):1574\u201382.","journal-title":"Clin Cancer Res"},{"issue":"1","key":"4153_CR30","doi-asserted-by":"publisher","first-page":"130","DOI":"10.1016\/j.ygyno.2017.01.030","volume":"145","author":"M Kentwell","year":"2017","unstructured":"Kentwell M, Dow E, Antill Y, Wrede CD, McNally O, Higgs E, et al. Mainstreaming cancer genetics: a model integrating germline BRCA testing into routine ovarian cancer clinics. Gynecol Oncol. 2017;145(1):130\u20136.","journal-title":"Gynecol Oncol"},{"issue":"12","key":"4153_CR31","doi-asserted-by":"publisher","first-page":"690","DOI":"10.12968\/bjon.2016.25.12.690","volume":"25","author":"N Percival","year":"2016","unstructured":"Percival N, George A, Gyertson J, Hamill M, Fernandes A, Davies E, et al. The integration of BRCA testing into oncology clinics. Br J Nursing. 2016;25(12):690\u20134.","journal-title":"Br J Nursing"},{"key":"4153_CR32","doi-asserted-by":"publisher","first-page":"3156","DOI":"10.1038\/ncomms4156","volume":"5","author":"KL Kanchi","year":"2014","unstructured":"Kanchi KL, Johnson KJ, Lu C, McLellan MD, Leiserson MD, Wendl MC, et al. Integrated analysis of germline and somatic variants in ovarian cancer. Nat Commun. 2014;5:3156.","journal-title":"Nat Commun"}],"container-title":["BMC Cancer"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-018-4153-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,10,12]],"date-time":"2019-10-12T02:27:04Z","timestamp":1570847224000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmccancer.biomedcentral.com\/articles\/10.1186\/s12885-018-4153-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,3,5]]},"references-count":32,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2018,12]]}},"alternative-id":["4153"],"URL":"https:\/\/doi.org\/10.1186\/s12885-018-4153-8","relation":{},"ISSN":["1471-2407"],"issn-type":[{"value":"1471-2407","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,3,5]]},"assertion":[{"value":"11 July 2017","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 February 2018","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 March 2018","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Ethics approval for this study was obtained from the University of British Columbia\u2019s Behavioural Research Ethics Board (H14\u201302280). Patient consent was not required.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Publisher\u2019s Note"}}],"article-number":"254"}}